Innealta Capital LLC Makes New $65,000 Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Innealta Capital LLC acquired a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,025 shares of the specialty pharmaceutical company’s stock, valued at approximately $65,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. AJOVista LLC bought a new stake in ANI Pharmaceuticals in the fourth quarter worth approximately $58,000. Ridgewood Investments LLC acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $85,000. SG Americas Securities LLC bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at $106,000. ADAR1 Capital Management LLC bought a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at $132,000. Finally, Clear Street Markets LLC acquired a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at $140,000. 76.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity at ANI Pharmaceuticals

In related news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $64.41, for a total value of $1,288,200.00. Following the transaction, the senior vice president now owns 213,226 shares of the company’s stock, valued at approximately $13,733,886.66. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $64.41, for a total value of $1,288,200.00. Following the transaction, the senior vice president now owns 213,226 shares of the company’s stock, valued at approximately $13,733,886.66. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Stephen P. Carey sold 5,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $63.58, for a total transaction of $317,900.00. Following the transaction, the chief financial officer now directly owns 161,968 shares in the company, valued at approximately $10,297,925.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 93,992 shares of company stock valued at $5,897,630. 12.70% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $63.75 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.95 and a quick ratio of 3.12. The stock has a 50-day moving average of $62.08 and a 200-day moving average of $63.79. The company has a market cap of $1.34 billion, a PE ratio of 39.84 and a beta of 0.75. ANI Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. The business had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. During the same quarter last year, the firm earned $1.06 EPS. The firm’s revenue for the quarter was up 18.5% compared to the same quarter last year. On average, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 3.3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ANIP has been the subject of a number of research reports. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Truist Financial downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $82.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.